Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas
- 13 December 2019
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 25 (24), 7565-7575
- https://doi.org/10.1158/1078-0432.ccr-19-0976
Abstract
Purpose: This study was aimed at investigating whether the PPARg agonist pioglitazone - given in combination with trabectedin - is able to reactivate adipocytic differentiation in myxoid liposarcoma (MLS) patient-derived xenografts overcoming resistance to trabectedin. Experimental Design: The antitumor and biological effects of trabectedin, pioglitazone and the combination of the two drugs were investigated in nude mice bearing well-characterized MLS xenografts representative of innate or acquired resistance against trabectedin. Pioglitazone and trabectedin were given by daily oral and weekly i.v administrations, respectively. Molecular studies were performed by using microarrays approach, real-time PCR and Western blotting. Results: We found that the resistance of MLS against trabectedin is associated with the lack of activation of adipogenesis. PPARg agonist pioglitazone reactivated adipogenesis, assessed by histological and gene pathway analyses. Pioglitazone was well-tolerated and did not increase the toxicity of trabectedin. The ability of pioglitazone to reactivate adipocytic differentiation was observed by morphological examination, and it is consistent with the increased expression of genes such as ADIPOQ implicated in the adipogenesis process. The determination of adiponectin by Western blotting constitutes a good and reliable biomarker related to MLS adipocytic differentiation. Conclusions:The finding that the combination of pioglitazone and trabectedin induces terminal adipocytic differentiation of some MLSs with the complete pathological response and cure of tumor-bearing mice provides a strong rationale to test the combination of trabectedin and pioglitazone in patients with MLS.Keywords
Other Versions
Funding Information
- Italian Association for Cancer Research (19189)
This publication has 44 references indexed in Scilit:
- PPARγ agonists enhance ET-743–induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcomaJCI Insight, 2012
- Guidelines for the welfare and use of animals in cancer researchBritish Journal of Cancer, 2010
- Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution seriesAnnals of Oncology, 2009
- U2OS cells lacking Chk1 undergo aberrant mitosis and fail to activate the spindle checkpointJournal of Cellular and Molecular Medicine, 2009
- UPR Pathways Combine to Prevent Hepatic Steatosis Caused by ER Stress-Mediated Suppression of Transcriptional Master RegulatorsDevelopmental Cell, 2008
- FUS-DDIT3 Prevents the Development of Adipocytic Precursors in Liposarcoma by Repressing PPAR gamma and C/EBP alpha and Activating eIF4EPLOS ONE, 2008
- The NCI60 human tumour cell line anticancer drug screenNature Reviews Cancer, 2006
- The Myxoid/Round Cell Liposarcoma Fusion Oncogene FUS-DDIT3 and the Normal DDIT3 Induce a Liposarcoma Phenotype in Transfected Human Fibrosarcoma CellsThe American Journal of Pathology, 2006
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factorCell, 1994